Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes

Completed · Phase 1

Conditions studied: Type 2 Diabetes Mellitus

In brief

Study B1621019 will assess efficacy and safety of two different dosing regimens of an investigational agent (PF-04937319) compared to an approved drug (sitagliptin) in patients with type 2 diabetes

Key facts

Study ID

NCT01933672

Run by

Pfizer

People needed

33

Starts

2013-10-01

Expected to finish

2014-03-01

Last updated by the study team

2016-09-27

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with type 2 diabetes, on background metformin therapy either alone or with 1 other oral anti-diabetic agent (excluding Actos)

You may not qualify if…

• Patients with cardiovascular event within 6-months of screening
• Patients with diabetic complications
• Female subjects who are pregnant or planning to become pregnant
• Subjects with unstable medical conditions (eg, hypertension)

Where it is running

• Avail Clinical Research, LLC — DeLand, Florida, United States
• Miami Research Associates, Inc. — South Miami, Florida, United States
• MRA Clinical Research, LLC — South Miami, Florida, United States
• High Point Clinical Trials Center, LLC — High Point, North Carolina, United States
• Community Research — Cincinnati, Ohio, United States
• Clinical Trials of Texas, Inc — San Antonio, Texas, United States
• Diabetes and Glandular Disease Clinic — San Antonio, Texas, United States
• Spaulding Clinical Research, LLC — West Bend, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.